



Contact:

Robert Gottlieb
RMG Associates, LLC
857-891-9091
Robertmg52@gmail.com

Cellanyx Diagnostics' Live Cell Phenotypic Risk Stratification Test Data from 'Normal' Tissue Samples Recognized at AdMeTech Foundation's First Global Summit on Precision Diagnosis for Prostate Cancer with Second Place in Poster Competition

Beverly, MA, September 28, 2016 – Cellanyx Diagnostics' live cell phenotypic biomarker test data demonstrating the potential to stratify prostate cancer risk from 'normal' [field] tissue obtained away from the known area of tumor, was awarded second place in the poster competition at the AdMeTech Foundation's First Global Summit on Precision Diagnosis for Prostate Cancer, Sept. 16-18 in Boston, MA. This citation, along with Cellanyx's recent award for the best prostate cancer biomarker poster at the annual meeting of American Urological Association Annual meeting (May 2015, San Diego, CA), underscores the growing recognition of the potential for the company's live cell phenotypic biomarker platform. Cellanyx is developing a prostate cancer phenotypic biomarker test to assess tumor aggressiveness and metastatic potential. Cellanyx's test will complement the standard-of-care Gleason pathology scores to allow improved risk-stratification in prostate cancer.

Biopsies to detect prostate cancer sample less than one percent of the prostate gland, and as a result, about half of random prostate biopsies are negative and this leads to the need for re-biopsy in a significant percentage of men.

Cellanyx presented data from 60 prostate tissue samples taken at the time of radical prostatectomy (RP) from tissue away from the known area of cancer (referred to as 'field tissue' samples). The "field" samples were part of a larger blinded, multi-center clinical validation study in 250 RP specimens at the time of surgery.

-more-

The Cellanyx test predicted adverse pathology from both, the “field” and known tumor samples with greater than 85 percent sensitivity and specificity by Receiver Operator Curves (ROC) by Area Under the Curve (AUC) measurements. Cellanyx plans to conduct a prospective, clinical utility study in patients undergoing needle biopsies to compare its predictive phenotypic biomarker metrics to adverse pathologic features found in men who subsequently undergo RP.

The poster is entitled, “Analytical Validation of a Live-Cell Phenotypic Biomarker-Based Diagnostic Assay for the Prediction of Adverse Pathology in Prostate Cancer from Field Biopsy Cores.” Links: [poster](#) | [abstract](#).

About Cellanyx Diagnostics

Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company’s unique ‘biopsy-on-a-chip’ methodology provides quantitative, actionable assessment of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential. Cellanyx has demonstrated clinical proof-of-concept with its lead product in development, a diagnostic to improve risk stratification in men with prostate cancer. Learn more at www.cellanyx.com.

###